Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Raw Materials (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Raw Materials for 15 consecutive years, with $13.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Raw Materials fell 24.1% to $13.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $13.5 million, a 24.1% decrease, with the full-year FY2024 number at $15.3 million, down 0.9% from a year prior.
  • Raw Materials was $13.5 million for Q3 2025 at Harvard Bioscience, down from $14.8 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $19.2 million in Q2 2022 to a low of $13.5 million in Q3 2025.
  • A 5-year average of $16.3 million and a median of $15.7 million in 2023 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: surged 34.18% in 2021, then fell 24.1% in 2025.
  • Harvard Bioscience's Raw Materials stood at $18.5 million in 2021, then fell by 5.89% to $17.4 million in 2022, then dropped by 11.65% to $15.4 million in 2023, then dropped by 0.9% to $15.3 million in 2024, then dropped by 11.68% to $13.5 million in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Raw Materials are $13.5 million (Q3 2025), $14.8 million (Q2 2025), and $14.7 million (Q1 2025).